A conventional indirect immunofluorescence assay (IFA) and an anticomplement indirect immunofluorescence assay (ACIF) for detecting serum antibodies to Borrelia burgdorferi in humans were evaluated during a prevalence survey in northern California. Sera obtained from 119 current or former residents of an area in which Lyme disease is endemic were split and tested by the IFA in two laboratories and the ACIF in a third. The seropositivity rate ranged from 15 to 20% with 88 to 93% agreement among laboratories. Interlaboratory agreement was statistically highly significant in each of the three pairwise comparisons and was positively associated with clinical manifestations of Lyme disease. Intralaboratory agreement ranged from 93 to 96% in two laboratories and was also statistically highly significant. Immunoblotting confirmed 100 of 101 of the nondiscrepant immunoRluorescence test results and likewise was positively correlated with the degree of interlaboratory agreement. The ACIF was found to be a highly specific test (100% specificity) with a much lower cutoff titer (1:8) than the conventional IFA (determined to be 1:128 or 1:256 in two laboratories) for detecting antibodies to B. burgdorferi. It also appeared to be more sensitive (80 versus 68%) than the IFA as determined by comparative immunoblotting, though the absolute sensitivity of the ACIF for serodiagnosis of early Lyme disease has yet to be determined. Significant serologic cross-reactivity was demonstrated between B. burgdorferi, Borrelia coriaceae, and Borrelia hermsii by the IFA, which may confound spirochetal serosurveys in California where ail three spirochetes are known to coexist.
A prospective epidemiologic study of a population at high risk for Lyme disease was initiated in a small community (population, ca. 150) in northern California in 1988. Part of that investigation, which is being conducted in the Ukiah area of Mendocino County, involves a serosurvey of study participants for antibodies to Borrelia burgdorferi. However, serious concerns have been expressed about the lack of standardization and the reliability of serologic tests that are being used routinely for diagnosis of Lyme disease (14, 24, 33 ; H. W. Wilkinson, H. Russell, and J. S. Sampson, Letter, J. Clin. Microbiol. 21:291, 1985) . The serodiagnosis of Lyme disease in the far western United States, especially in California, may be confounded further by the occurrence in that region of other species of tick-borne borreliae that cross-react serologically with B. burgdorferi (29) . These include three species of relapsing fever spirochetes (B. hermsùi, B. parkeri, and B. turicatae) and the recently described B. coriaceae (17, 18) . Indeed, it has been suggested recently that a chronic neuroborreliosis syndrome that is caused by B. burgdorferi and other borreliae (29) may occur in California, since it is known that various neurologic sequelae may be caused by both Lyme disease and relapsing fever spirochetes (10, 25, 26, 29, 30, 34, 35) .
Therefore, serum specimens obtained from subjects at entry into the northern California epidemiologic study were subjected to a three-way interlaboratory comparison; this was done to determine the agreement between and the reliability of the conventional indirect immunofluorescence assay (IFA) in the research laboratories of R.S.L. and J.E.M. and the anticomplement indirect immunofluorescence assay (ACIF) in the commercial reference laboratory of E.T.L. We selected indirect immunofluorescence for * Corresponding author.
comparison because this assay is presently being used for serodiagnosis of Lyme disease in many commercial laboratories that test for Lyme disease in California.
The specific objectives of this study were to compare the results of the three indirect immunofluorescence assays for detecting antibodies to B. burgdorferi among members of the population at high risk for Lyme disease, to conduct an intralaboratory comparison with the same sera in the two laboratories using the conventional IFA, to determine the degree of serologic cross-reactivity of the B31 strain of B. To establish the cutoff titers, 115 serum specimens from residents of the San Francisco, Calif., metropolitan area who had no known history of Lyme disease were used as test control sera. They included 68 serum specimens from individuals age and sex matched (34 males and 34 females) to 68 members of the high-risk population; 35 serum specimens from children between 6 and 24 months of age, when the risk of tick exposure is low; 6 serum specimens positive for rheumatoid factor; 5 serum specimens positive for antinuclear antibodies; and a single serum specimen from a syphilitic patient.
Sera from the high-risk population and the test control population were blind coded, split three ways, and tested in each laboratory. Hereinafter, the three laboratories are designated as A, B, and C. The sera were decoded upon completion of the serologic testing. The results from the test control sera were used to determine the cutoff titer only; they were not used in analyzing the epidemiologic data.
Antigens. The type strain of B. burgdorferi (B31), from Shelter Island, N.Y., was grown at each site and used as the primary antigen in all three laboratories. The spirochetes were grown in BSK-II medium (3), except that horse serum was substituted for rabbit serum in laboratory C. The cultures were grown for 5 to 7 days, and the cells were harvested by centrifugation (8, 200 x g) for 30 min. The organisms were washed in either phosphate-buffered saline (PBS) or PBS-5 mM magnesium chloride one to three times and diluted to approximately 100 organisms per high dry field (magnification, x400). In the conventional IFA, 10 to 20 ,tl of the suspensions was added to each well of Teflon-coated microscope slides, air dried, and fixed in either 100% methanol for 3 serum specimens were reactive at <1:8. Hence, the cutoff titers were set at 1:128, 1:256, and 1:8 for laboratories A, B, and C, respectively, to achieve the desired test specificity of .99%. Notably, only one of the three highest-titered serum specimens in laboratory A also was reactive in laboratory B, and none was from patients with autoimmune diseases. Moreover, none of the four serum specimens producing titers .1:128 in laboratory A or B was positive by immunoblotting.
Sera from a high-risk population. With the above cutoff titers, the seropositivity rate detected for the population residing in the area in which Lyme disease is hyperendemic varied from 15 to 20% among laboratories. The resultant pairwise interlaboratory agreement ranged from 88 to 93% and was statistically highly significant in each of the three pairwise comparisons. The lowest agreement occurred between the two IFA procedures and between the IFA in laboratory A and the ACIF; the highest agreement was between the IFA in laboratory B and the ACIF ( Table 1) . The absolute interlaboratory agreement was 85%, since 87 serum specimens were negative and 14 were positive in all three laboratories. Of the remaining 18 serum specimens, 16 were positive in one laboratory and 2 were positive in two laboratories. The run-to-run agreement varied from 93% in laboratory A (K = 0.80) to 96% in laboratory B (K = 0.84) and was statistically highly significant in both laboratories (P < 0.000001). Titers for positive sera ranged from 1:128 to 1:1,024 in laboratory A, 1:256 to 1:4,096 in laboratory B, and 1:16 to 1:1,024 in laboratory C.
Immunoblot results. While the overall agreement among laboratories was highly significant, there were discrepancies. To resolve interlaboratory disagreements and to validate interlaboratory agreements, immunoblotting was performed on ail 119 test serum samples. Of the 32 serum specimens positive by the IFA, the ACIF, or both, 24 (which included all 14 nondiscrepant sera and 10 of 18 discrepant sera) were confirmed as positive by Western blot analysis ( Table 2 ). The percentages of the 24 serum specimens confirmed by Western blot analysis that were IFA or ACIF positive in laboratory A, B, or C were 71, 71, and 83%, respectively. Of the 87 serum samples that were negative in all three laboratories, 1 was positive by immunoblot analysis while 3 were indeterminate. The latter sera were reactive primarily to the 40-kDa polypeptide and did not meet the criteria for positivity. Twenty-one of the 25 Western blot-positive serum specimens were strongly reactive and 4 were weakly reac- tive to outer surface polypeptides specific for B. burgdorferi, i.e., those having relative mobilities of ca. 31 to 32 and 34 to 35 kDa. Also, three HATTS-positive serum specimens that were positive in all three laboratories by the IFA and the ACIF for B. burgdorferi also were Western blot positive against the B31 antigen. Clinical correlates. Questionnaires were filled out by 93 of the 99 participating current residents and by 10 of 20 former residents whose sera were assayed for antibodies to B. burgdorferi. As summarized in Table 3 , 79% of the subjects whose sera were reactive in all three laboratories reportedly had one or more clinical manifestations consistent with a diagnosis of Lyme disease, and, in fact, 85% of them had been diagnosed with the disease before entry into the study by their physicians. Among the 15 subjects whose sera were reactive in just one laboratory, only 33% had signs or symptoms suggestive of Lyme disease and only 29% had been diagnosed previously with the disease.
Cross-reactivity between B. burgdorferi B31 antigen and other spirochetal antigens. Twenty-four serum specimens that were positive by IFA in laboratory A were retested with B. burgdorferi CA5, B. coriaceae C053, and B. hermsii HS1 (Table 4 ). There was considerable cross-reactivity with all three antigens. In the comparison involving the two B. burgdorferi strains, B31 and CA5, 11 of 24 serum specimens had two-to eightfold higher titers to B31, 10 had identical titers to both strains and 3 had twofold higher titers to CA5. When B31 was compared with B. coriaceae C053, 17 serum specimens had two-to greater than eightfold higher titers to B31, 6 had identical titers to both, and 1 had a twofold higher titer to C053. Similarly, when B31 was compared with B. hermsii HS1, 21 serum specimens yielded two-to greater than eightfold higher titers to B31, 2 had identical titers to both, and 1 had a higher titer to HS1. If a cutoff titer of 1:128 had been selected for CA5, B. coriaceae, and B. hermsii, then 5 of the 24 serum specimens would have been negative for CA5, 9 would have been negative for C053, and 11 would have been negative for HS1 in comparison with B31.
DISCUSSION
In a previously reported interlaboratory comparison in Minnesota involving four laboratories, the seropositivity rate obtained by participants for identical samples varied widely from 0 to 35% (14) . In that report, a single procedure (IFA) was used with a uniform cutoff titer of 1:256. On the basis of the significantly different results obtained, the authors concluded that a lack of standardization in serologic testing can lead to significant variation in results as well as to difficulties in interpreting the full clinical spectrum of Lyme disease.
Similarly, serum specimens from 132 outdoor workers in New Jersey were tested for antibodies to Lyme disease in as many as four independent laboratories to evaluate inter-and (14) 4 (29) 9 (75) 1 (8) 5 (36) 3 (21) 11 (85) 2 (2) 2 (100) 2 (100) 0 (0) 1 (100) 0 (0) O (0) 1 (15) 2 (13) 4 (27) 1 (7) 2 (14) 10 (67) 4 (29) Total 8 (26) 15 (52) 2 (7) 8 (27) 13 (42) 15 (52) a Not all subjects responded to every question concerning clinical manifestations, and therefore the percentages tabulated here are based on slightly reduced sample sizes in several instances.
intralaboratory agreement (33) . Two laboratories performed IFA and two performed enzyme-linked immunosorbent assays, and each laboratory had a different cutoff to determine seropositivity. Interlaboratory agreement, as measured with the K statistic, was consistently low to moderate (K values ranged from 0.45 to 0.53), as was intralaboratory agreement in a single commercial laboratory. The authors concluded that the lack of interlaboratory agreement indicates that the methods, antigens, and reagents used for the serodiagnosis of Lyme disease should be standardized statewide.
In contrast to the reports described above, we found that there was a statistically highly significant agreement within each of two laboratories as well as among all three laboratories (Table 1 ). In the design of the experiment, the selection of the procedure to be used in each laboratory was discretionary, and the reagents were prepared individually by the participants. However, each participant agreed to use B. burgdorferi B31 antigen as the primary antigen, to eval- B31  CAS  C053  HS1   2  512  64  <64  <64  8  256  64  <64  <64  9  256  256   64  <64  14  256  512  256  512  30  1,024  256  512  256  32  1,024  512  512  512  39  128  128  64  <64  40  128  64  64  <64  45  512  512  256  128  53  128  64  128  <64  65  512  512  512  256  67  256  512  512  256  70  512  512  512  256  71  512  512  <64  128  75  512  512  512  512  77  256  512  128  128  79  256  128  128  64  92  512  512  512  64   94  128  128  64  64   95  1,024  512  512  512  100  512  128  128  128  101  512  256  256  256  110  128  <64  64  64  113  128  128 64 64 uate the test and control panels in a blind fashion, to determine the reproducibility of each subject's results with repeat testing, and, finally, to determine the sensitivity and specificity of the procedure used in his or her laboratory against a reference immunoblotting procedure performed in laboratory A. It was anticipated that the cutoff titer established for each laboratory would be affected by differences in the procedures used, how reagents were prepared, which microscopes were available, and the reading standards. It was decided that absolute standardization for those four factors would not be feasible or necessary. Rather than adopting a standardized cutoff titer, the participating laboratories decided that the cutoff titer should be established within each laboratory to minimize the effects of potential interprocedural and interlaboratory differences. This was accomplished effectively by setting a test specificity of 99% as a criterion on the basis of results obtained from testing 115 negative control serum specimens.
Immunoblotting confirmed 99% of the nondiscrepant results and correlated well with the agreement between laboratories. In 100 of 101 instances in which a serum was positive (n = 14) or negative (n = 87) in all three laboratories, it was confirmed by Western blot analysis. Conversely, only 56% of discrepant sera were confirmed by Western blot analysis. Of the two immunofluorescence procedures, the ACIF appeared to be more sensitive and specific. Relative to the immunoblotting assay, the sensitivity and specificity were 80 and 100% for the ACIF, 68 and 99% for the IFA in laboratory B, and 68 and 93% for the IFA in laboratory A.
Interlaboratory agreement in seroreactivity was positively associated with clinical manifestations of Lyme disease (Table 3) . Subjects whose sera were reactive in all three laboratories were more than twice as likely to have reported one or more manifestations (i.e., arthritic, cardiac, dermatologic, or neurologic manifestations) associated with Lyme disease and three times as likely to have been diagnosed with the disease before entry into the study than subjects whose sera were reactive in a single laboratory. Three (21%) of fourteen subjects whose sera were reactive in all three laboratories reported that they had not experienced manifestations of Lyme disease. One of them had been diagnosed with and treated for Lyme disease on the basis of an earlier positive serologic test result, whereas the two remaining subjects are being monitored prospectively to determine whether they will develop the disease. Overall, subclinical infections occurred in 10 (42%) of 24 subjects whose sera were positive by both the IFA (i.e., in one or more laboratories) and immunoblotting and who completed a questionnaire. Among the 93 current residents of the test population who participated in this study, 9 (9.7%) had subclinical infections. Likewise, 6.8 to 9.0% of residents of Fire Island, VOL. 28, 1990 on October 19, 2017 by guest http://jcm.asm.org/ Downloaded from N.Y., Great Island, Mass., and Middletown, Conn., had asymptomatic infection with B. burgdorferi (7, 13, 37) .
Serologic cross-reactivity between B. burgdorferi and other spirochetes, particularly borreliae and treponemes, has been demonstrated previously (2, 8, 16, 21, 22, 27, 28, 31, 39) . Sera from patients with a variety of other clinical conditions (e.g., autoimmune disorders, human immunodeficiency virus infection, infectious mononucleosis, multiple sclerosis, rheumatoid arthritis, or Rocky Mountain spotted fever) also cross-react with B. burgdorferi in serologic tests (20, 21, 23, 27, 28, 36) . We detected considerable serologic cross-reactivity between B. burgdorferi and antigens prepared from each of two other tick-borne borreliae (B. coriaceae and B. hermsii) that occur naturally in California (Table 4) . Cross-reactivity between B. burgdorferi and the relapsing fever spirochete B. hermsùi has been recorded for both human and coyote sera by others (6, 21, 22, 27) , but cross-reactivity between B. burgdorferi and B. coriaceae has not been reported previously. In California, B. hermsii occurs predominantly in mountainous regions above 5,000 ft (1,524 m) (40), which do not include coastal counties such as Mendocino, the source of the sera evaluated in the present investigation. In contrast, B. coriaceae has been isolated only in Mendocino County from its soft tick vector, O. coriaceus (18) . Although B. coriaceae is not known to cause human infection, O. coriaceus bites humans occasionally and reactions to its bite may produce systemic reactions in some individuals (9, 15) . When the 24 IFA-positive sera in laboratory A were retested with B. burgdorferi (two strains), B. coriaceae, and B. hermsii as sources of antigens, many of the sera reacted equally well to two or more of these antigens. It is impossible to ascertain from the antibody titers alone which species of the genus Borrelia was the actual infecting organism. In our study, the degree of crossreactivity was greatest between B. burgdorferi and B. coriaceae and least between the former and B. hermsii.
Cross-reactivity between B. burgdorferi and Treponema pallidum was not found to be a major problem in our study. Only 3 of 32 B. burgdorferi-positive serum specimens also reacted in the HATTS, two with titers of 1:16 and one with a titer of 1:32. Western blot analysis revealed that the immunoglobulin present in these three serum specimens were indeed directed against B. burgdorferi-specific antigen bands (i.e., 31-and 34-kDa polypeptides). Further, illnesses experienced by two of the individuals with B. burgdorferiand HATTS-positive sera met a standardized case definition for Lyme disease. Although serologic cross-reactivity between B. burgdorferi and T. pallidum has been reported, antibodies to B. burgdorferi usually do not react in the microhemagglutination test for T. pallidum antibody, the rapid plasma reagin test, the Venereal Disease Research Laboratory assay, or as demonstrated here, in the HATTS (8, 16, 31) .
In addition to interspecies cross-reactivity, we also examined intraspecies differences, i.e., between B. burgdorferi B31 and CA5. Previous reports indicated no significant serologic differences between B. burgdorferi isolates from the United States and Europe by IFA (1, 2, 31, 39) . Russell et al. (31) , for example, tested 12 serum specimens from residents of Minnesota and New Jersey with five isolates of B. burgdorferi (two from humans and three from ticks) and found that all five isolates produced similar results within a twofold dilution factor. In contrast, 5 of 24 (21%) serum specimens in the present study differed significantly in their production of antibodies against B31 and CA5 (Table 4 ). These differences may be due to a disparity in the in vitro passage level between the 2 cultures. Rapid antigenic changes and loss of one of the major outer surface proteins (OspB) in B. burgdorferi have been observed following its short-term (10 to 15 passages) in vitro cultivation in BSK-II medium, and this phenomenon must be considered when the results of spirochetal serosurveys are being interpreted (32) . In addition, significant variations even exist in the major outer surface proteins (OspA and OspB) and other proteins (21 to 25 kDa) in fresh tick-derived isolates of B. burgdorferi from northern California (5, 19) . Isolate CA5 possessed abundant proteins with relative mobilities of ca. 21.5 and 24 kDa that were not present in several other fresh isolates from ticks or in the B31 strain used as a control in this study (19) . This is the first report describing the use and validity of the ACIF for detecting antibodies to B. burgdorferi. The fact that only true antigen-antibody complexes (versus nonspecific antibody binding or Fc receptor-antibody reactions) can be detected with guinea pig complement and fluorescein isothiocyanate-labeled anti-guinea pig complement C3 component in this assay significantly reduces the nonspecific reactivity that may occur in the conventional IFA. Unlike the IFA, which usually exhibits gradual loss of intensity with decreasing antibody concentration, the staining observed in the ACIF has very sharp, reproducible endpoints that facilitate quantitation and interpretation. Therefore, a cutoff titer ofonly 1:8 was found to confer a test specificity of 100% with no apparent reduction in sensitivity relative to the IFA as determined by comparative immunoblotting. These findings establish that the ACIF is a useful serodiagnostic tool for Lyme disease. However, its absolute sensitivity for detecting antibodies in individuals experiencing the early stages of the disease remains to be determined.
In conclusion, a three-way interlaboratory comparison using independently developed procedures showed that significant agreement can be obtained in the serodiagnosis of Lyme disease provided that participating laboratories adhere to a uniform standard for test specificity.
